KRAS mutations are found in 15% to 20% of tumors, mostly leukemia, colorectal, pancreatic, and lung cancers. These mutations are reported in 30 % to 40 % of colorectal cancers and 15 % to 30 % of lung cancers. EGFR inhibitors are currently used to treat colorectal and non-small cell lung cancers. The KRAS mutation test is used to see if cancer cells are prone and respond to treatment. There are a few different tests to check for the KRAS mutations, mostly using tissues. OKras was developed to detect KRAS mutations in whole blood.